Document text
Principal Investigator: Karl Gorzelnik
Organization: LYNNTECH, INC.
Fiscal Year: 2024
Award: $283,304
Funding agency: National Institute of General Medical Sciences
PROJECT SUMMARY
Self-amplifying RNAs (saRNAs) are derived from single-stranded RNA (ssRNA) viruses, with the genes for the
viral structural proteins removed and replaced with a gene(s) of interest. The viral genes remaining in the self-
amplifying RNA encode the non-structural proteins which form the machinery necessary to replicate the RNA.
With the RNA undergoing repeated rounds of replication in the host cell, there is increased production of the
proteins of interest over a longer period compared with conventional mRNAs. The use of self-amplifying RNAs,
as opposed to conventional mRNAs, reduces the amount of RNA required to achieve similar responses.
Already, there are saRNAs in clinical trials by major pharmaceutical companies. The self-amplifying RNAs do
not further infect cells, as there are no structural proteins to form infectious progeny. During replication, the
positive-strand RNA is used as a template to make a negative-strand product which is then used as a template
for subsequent generation of more positive-strands and, subsequently, more of the desired protein. The goal of
our proposed study is to develop software that will optimize RNA replication when administering saRNA
vaccines and therapeutics. We will use a machine learning approach to develop software optimize to the
replicability of an RNA. That way when using the viral replicative machinery in self-amplifying RNAs the RNA
can replicate repeatedly, increasing the duration of expression for cargo genes of interest. We will test this
system and present data for at least three individual RNA genes optimized. One of the major impacts of our
proposed study will be the optimization of self-amplifying RNA therapeutics, which have been used for multiple
indications including infectious diseases and cancer. Self-amplifying RNAs require less RNA to be
administered, as compared to non-amplifying messenger RNAs, and have prolonged responses. Optimization
of the genetic cargo of self-amplifying RNAs is a critical step in their development as therapeutics and
vaccines. Yet, the only software to optimize protein production in self-amplifying RNAs is still anchored in
translation optimization from a single RNA, not to increase replication of RNAs. Our product adds another tool
in the toolbox for the development of self-amplifying RNAs. Just as many different approaches were combined
to make conventional RNA therapy possible, our methodology can synergize with other techniques to increase
protein production by self-amplifying RNAs.
Terms: <Address><Biology><Cancers><Cell Body><Cells><Clinical Trials><Codon><Codon Nucleotides><Communicable Diseases><Computer software><DNA Sequence><Data><Development><Future><Gene Expression><Generations><Genes><Genetic><Genetic Alteration><Genetic Change><Genetic defect><Goals><Health><Human><Immunoactivators><Immunoadjuvants><Immunologic Adjuvants><Immunopotentiators><Immunostimulants><In Vitro><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Knowledge><Lactase><Lactase Enzyme><Lactose Galactohydrolase><Left><Luciferase Immunologic><Luciferases><Machine Learning><Malignant Neoplasms><Malignant Tumor><Messenger RNA><Methodology><Modern Man><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Mutation><Non-Polyadenylated RNA><Non-structural Protein><Nonstructural Protein><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Process><Production><Proteins><Publications><RNA><RNA Gene Products><RNA Sequences><RNA Viruses><RNA amplification><RNA based therapeutics><RNA based therapy><RNA replication><RNA therapy><RNA vaccine><RNA-based vaccine><Research><Ribonucleic Acid><Scientific Publication><Self Administered><Self Administration><Software><Solid><Speed><Spikevax><Spinal Column><Spine><Structural Protein><Structure><System><Techniques><Testing><Therapeutic><Training><Translating><Translations><Vaccine Antigen><Vaccines><Vertebral column><Viral><Viral Genes><Viral Structural Proteins><Virus><backbone><develop software><developing computer software><developmental><genome mutation><in vivo><interest><mRNA><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><machine based learning><malignancy><native protein drug><neoplasm/cancer><peptide aminoacid sequence><peptide sequence><pharmaceutical><pharmaceutical protein><programs><protein aminoacid sequence><protein drug agent><protein expression><protein-based drug><replicase><response><software development><structural viral genes><success><synergism><therapeutic RNA><therapeutic protein><tool><translation><vector><viral RNA><virus RNA>